Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Ouyang Zheng
Methodist Hospital Research Institute, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
PurSpec Technologies, Inc.;
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
• The basis for (possible) FCOI determination is the following:
o The aim of the sub-contract to Purdue is to develop a portable nanodisk/mass spectrometry system for detecting active TB in children. PurSpec Technologies, Inc. develops and commercializes miniature mass spectrometry systems for chemical analysis. Therefore, the outcome of the TMHRI sponsored project at Purdue may impact/inform the business scope and activities of this entity.
Quantification of Circulating Antigens for Pediatric TB Diagnosis and Treatment Monitoring
Clinical diagnosis of TB disease in the highly vulnerable HIV-infected children is extremely challenging given the paucibacillary (few bacteria) nature of the disease and difficulties in obtaining relevant specimens. In this project, we implement a rapid nano-sensing and monitoring platform that combines the sophistication of mass- produced porous nanodisk fabrication, peptide-enrichment, and the powerful capabilities of bench-top MALDI mass spectrometry (MS) and/or a portable MS system specially developed for resource-limited area -- for detection and quantification of two TB-specific biomarkers (CFP-10 and ESAT-6) in patients' blood. Based on our preliminary studies, we are confident that this high-impact strategy could decrease the likelihood of disease progression, improve therapeutic regimens, and prevent the emergence of severe drug resistance strains.
Filed on May 19, 2016.
Tell us what you know about Ouyang Zheng's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Ouyang Zheng”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Ouyang Zheng | Methodist Hospital Research Institute | Conflict of Interest | TsingPu Technologies | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.